Elopag 25 (Eltrombopag) 25 mg Tablets

Indicated for adult patients and, in some cases, pediatric patients as prescribed by a physician for the following conditions:

• 🔹 Chronic Immune Thrombocytopenia (ITP): in patients with insufficient response to corticosteroids, immunoglobulins, or splenectomy.
• 🔹 Thrombocytopenia associated with chronic hepatitis C: to allow initiation and maintenance of antiviral therapy.
• 🔹 Severe Aplastic Anemia: in patients with inadequate response to immunosuppressive therapy.

Packaging: 25 mg tablets.

⚠️ ADMINISTRATION PROTOCOL:

• Starting Dose: Determined individually by the physician depending on indication, platelet count, and patient condition.
• Food Intake: Take on an empty stomach or with a meal low in calcium.
• Important: Do not take together with dairy products, antacids, or products containing calcium, magnesium, aluminum, iron, selenium, or zinc. A gap of at least 4 hours is recommended.
• Monitoring: Regular monitoring of platelet count, liver function, and complete blood count is required.
• Note: Dose adjustments should only be made by the treating physician based on laboratory results.

• Hypersensitivity to Eltrombopag or any component of the product.
• Use with caution in severe hepatic impairment.
• Risk of thromboembolic complications.
• Pregnancy and breastfeeding — only if clearly prescribed by a physician when benefits outweigh risks.

Common and clinically important adverse reactions include:

• 🩸 Blood/Vascular: Risk of thrombosis and thromboembolism if platelet counts rise excessively.
• 📉 Gastrointestinal: Nausea, diarrhea, abdominal pain, decreased appetite.
• 🧪 Liver: Elevated liver enzymes, hepatotoxicity.
• 💢 General: Headache, weakness, fatigue.
• 👁 Other: Possible cataract progression with long-term use.